Paul S. Jin

Paul Jin is a partner in Goodwin's Antitrust and Competition practice. Paul’s antitrust expertise covers a broad spectrum of commercial transactions, including mergers and acquisitions, B2B collaborations, and pricing and supply arrangements. Paul regularly serves clients by assessing transaction-related antitrust risk, negotiating terms of agreements, and determining the applicability of merger clearance filing requirements in both US and foreign jurisdictions. Paul routinely advocates on behalf of clients before the FTC, DOJ, and state regulators in connection with informal inquiries, Second Requests, third-party subpoenas, and conduct investigations. He also provides antitrust counseling on issues such as diligence and pre-closing conduct procedures, internal compliance programs, hiring and non-compete agreements, vendor agreements, interlocking directorates, and competitor collaboration guidelines. He has extensive knowledge of the Hart-Scott-Rodino (HSR) regime and has filed hundreds of notification forms with the FTC and DOJ for mergers, minority investments, asset acquisitions, and corrective fillings.

Prior to joining Goodwin in 2018, Paul was a partner in the antitrust practice at Wilson Sonsini Goodrich & Rosati, and previously practiced at Fried, Frank, Harris, Shriver & Jacobson LLP.

Select representations include:

• Biotheus in its definitive agreement to be acquired by BioNTech for $800 million upfront and up to $150 million in milestones
• Evisort in its acquisition by Workday
• Talon Cyber Security in its definitive agreement to be acquired by Palo Alto Networks
• Nanobiotix in its licensing, co-development, and commercialization agreement with Janssen for up to $1.8 billion
• eMagin Corporation in its acquisition by Samsung Display for $218 million
• Berkshire Grey in its definitive merger agreement to be acquired by SoftBank Group
• Marlin Equity Partners in its acquisition of Meltwater
• Nimbus Therapeutics in its sale of Allosteric Tyk2 Inhibitor Program to Takeda for $4 billion upfront and up to $6 billion total following antitrust litigation against Celgene and Bristol Myers Squibb to enjoin their attempted acquisition of the same program 
• Jemincare in its exclusive worldwide license agreement with Roche and Genentech for the development and commercialization of its androgen receptor degrader
• Thoma Bravo in its acquisition of Nearmap for AUD $1.055 billion
• Klaviyo in its product partnership with Shopify and on Shopify’s strategic investment in Klaviyo
• Coalition in its $250 million Series F financing
• BridgeBio Pharma in its exclusive license agreement with Bristol Myers Squibb for up to $905 million and sale of rare pediatric disease priority review voucher for $110 million
• Slack Technologies, Inc. in its $27.7 billion acquisition by Salesforce
• Virtusa Corporation in its $2 billion acquisition by Baring Private Equity Asia
• Lucid Holdings in its $1.1 billion acquisition by Cint Group AB
• Great Hill Partners in its acquisition of a controlling equity stake in Clearwave Parent, Inc. at an enterprise value of $300 million
• The creation of Beth Israel Lahey Health
• Twilio in its acquisition of SendGrid
• The independent directors of Sprint Corporation in their merger with T-Mobile USA
• PillPack, Inc. in its acquisition by Amazon
• Qualtrics in its acquisition by SAP SE
• AppNexus in its acquisition by AT&T
• Moovit in its acquisition by Intel

Paul is recommended for Antitrust - Merger Control and Healthcare: Life Sciences by The Legal 500 US (2019-2024). Paul Jin was recognized by LMG Life Sciences Americas Awards 2023 for Impact Deal of the Year Award as a member of the team which advised Sichuan Kelun-Biotech Biopharmaceutical in its $9.5 billion exclusive license and collaboration agreement with Merck to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.

• Co-author, “FTC and DOJ Finalize Major Changes to HSR Form and Disclosure Requirements,” Goodwin Client Alert, October 2024
• Co-author, “2024 HSR Thresholds Announced: $119.5 million,” Goodwin Client Alert, January 2024
• Co-author, “FTC Sues Private Equity Firm Welsh Carson and U.S. Anesthesia Partners Over Alleged Anesthesiology ‘Roll-Up Scheme’ in Texas,” Goodwin Client Alert, September 2023
• Co-author, “US Antitrust Agencies Release Revised Draft Merger Guidelines,” Goodwin Client Alert, July 2023
• Co-author, “FTC and DOJ Propose Major Changes to HSR Form and Disclosure,” Goodwin Client Alert, June 2023
• Co-author, “2023 HSR Thresholds Announced: $111.4 million,” Goodwin Client Alert, January 2023
• Co-author, “New Appropriations Bill Reforms Antitrust Laws and Modifies HSR Fees,” Goodwin Client Alert, January 2023
• Co-author, “DOJ and FTC Start Joint Effort To ‘Strengthen Enforcement Against Illegal Mergers’,” Goodwin Client Alert, January 2022
• Co-author, “2022 HSR Thresholds Announced: $101 Million,” Goodwin Client Alert, January 2022
• Co-author, “Biden Executive Order Calls for Heightened Antitrust Scrutiny,” Goodwin Client Alert, July 2021
• Co-author, “U.S. Supreme Court Significantly Restricts FTC Civil Enforcement Powers in AMG Capital Decision,” Goodwin Client Alert, May 2021
• Co-author, “2021 HSR Thresholds Announced: $92 Million,” Goodwin Client Alert, February 2021
• Co-author, “FTC Announces New Thresholds for 2020,” Goodwin Client Alert, January 2020
• Co-author with T. Hahn, “Merger Control 2019,” Global Legal Insights, June 2019
• Co-author, “Board Interlocks on Antitrust Enforcement Hot Seat: A Must-Read Guide for Board Members and Officers,” Goodwin Client Alert (March 2019)
• Co-author, “FTC’s New Technology Task Force Signals More Antitrust Scrutiny,” Goodwin Client Alert, February 2019
• Co-author, “FTC Announces New Thresholds For 2019,” Goodwin Client Alert, February 2019
• Co-author, “Top Antitrust Developments for 2018,” Goodwin Insights, January 2019
• Co-author with T. Hahn and A. Murino, “Merger Control 2018,” Global Legal Insights, July 2018
• Co-author, “DOJ Stomping Out “No Hire” Agreements Among Competitors,” Goodwin Client Alert, April 2018
• Co-author with C.A. Williams and R.E. Comerford, “U.S.” chapter, Merger Control, Sixth Edition, Global Legal Insights, 2017
• Contributing Author, Premerger Notification Practice Manual, Fifth Edition, American Bar Association, 2015
• Co-author with C.A. Williams, “U.S.” chapter, Merger Control, Fourth Edition, Global Legal Insights, 2015
• Contributing Author, The Merger Review Process, Fourth Edition, American Bar Association, 2012
• Co-author with C.E. Biggio, “The United States: An Ideal Merger Review Process?,” 2007 Annual Fall Conference on Competition Law, Canadian Bar Association, National Competition Law Section, October 2007

Speaking engagements:

• Speaker, “Private Equity Planning for Post COVID-19: An Antitrust Roadmap for PE Investment,” Goodwin Webinar, July 2020
• Speaker, “Life Sciences Deals & Antitrust in the Age of COVID-19,” Goodwin Webinar, May 2020
• Panelist, “Caveat Emptor: When are buying groups illegal?” ABA Section of Antitrust Law Spring Meeting, Washington, D.C., April 2016
• Speaker, “The Hart-Scott-Rodino Act: Recognizing Covered Transactions,” Knowledge Group Webcast, February 2016
• Speaker, “Mitigating Antitrust Risks in Mergers & Acquisitions Transactions: What Every Firm Needs to Know in 2015,” Knowledge Group Webcast, June 2015